CA2779282C - Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment - Google Patents

Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Download PDF

Info

Publication number
CA2779282C
CA2779282C CA2779282A CA2779282A CA2779282C CA 2779282 C CA2779282 C CA 2779282C CA 2779282 A CA2779282 A CA 2779282A CA 2779282 A CA2779282 A CA 2779282A CA 2779282 C CA2779282 C CA 2779282C
Authority
CA
Canada
Prior art keywords
patient
cancer
diet
fasting
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2779282A
Other languages
English (en)
French (fr)
Other versions
CA2779282A1 (en
Inventor
Valter D. Longo
Changhan Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CA2779282A1 publication Critical patent/CA2779282A1/en
Application granted granted Critical
Publication of CA2779282C publication Critical patent/CA2779282C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2779282A 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Active CA2779282C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US61/254,154 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (2)

Publication Number Publication Date
CA2779282A1 CA2779282A1 (en) 2011-04-28
CA2779282C true CA2779282C (en) 2017-12-05

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779282A Active CA2779282C (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Country Status (13)

Country Link
US (2) US20110118528A1 (enExample)
EP (1) EP2490684B1 (enExample)
JP (1) JP2013508411A (enExample)
CN (1) CN102753162A (enExample)
AU (2) AU2010310515B2 (enExample)
BR (1) BR112012009423A2 (enExample)
CA (1) CA2779282C (enExample)
DK (1) DK2490684T3 (enExample)
ES (1) ES2659353T3 (enExample)
PL (1) PL2490684T3 (enExample)
PT (1) PT2490684T (enExample)
RU (1) RU2549954C2 (enExample)
WO (1) WO2011050302A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066426A1 (en) 2012-10-22 2014-05-01 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
EP3510875B1 (en) * 2013-02-12 2020-06-10 University of Southern California Diet composition for use in a therapeutic method of lowering blood glucose and/or igf-1 levels
CN105431055A (zh) 2013-07-01 2016-03-23 南加利福尼亚大学 作为糖尿病食疗的禁食条件
MX383483B (es) * 2014-03-06 2025-03-14 Univ Southern California Utilización de régimen de ayuno a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales e invertir los efectos secundarios de cinasas en células y tejidos normales.
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3122354B1 (en) 2014-03-28 2022-06-15 Universita' degli Studi di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
WO2015153850A2 (en) * 2014-04-02 2015-10-08 University Of Southern California Autoimmunity and multiple sclerosis treatment
HK1249858A1 (zh) 2015-04-16 2018-11-16 南加利福尼亚大学 响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件
US11000057B2 (en) 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
CN108601838A (zh) * 2015-09-21 2018-09-28 意大利癌症研究基金会分子肿瘤学研究所(Ifom) 对抗血液癌症的新治疗策略
HK1258621A1 (zh) * 2016-01-12 2019-11-15 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其他癌症的膳食治疗的用途
BR112018016494A2 (pt) 2016-02-15 2018-12-26 University Of Southern California método para promover regeneração de célula pancreática e reprogramação de célula somática; e pacote de dieta
EP3419615A1 (en) 2016-02-23 2019-01-02 Cancer Research Technology Ltd. Dietary product devoid of at least two non essential amino acids
CN109152790A (zh) 2016-05-11 2019-01-04 南加利福尼亚大学 禁食模仿膳食作为胃肠自身免疫性/炎性疾病的免疫调节治疗剂
IT201700008499A1 (it) 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
BR112020018564A2 (pt) 2018-03-15 2020-12-29 University Of Southern California Composição probiótica para doença gastrointestinal autoimune e/ou inflamatória, uso de uma dieta que simula jejum para prevenir ou tratar doença gastrointestinal autoimune e/ou inflamatória, e suplemento dietário
US20210267250A1 (en) * 2018-07-18 2021-09-02 Andreas Michalsen Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
JP2022515707A (ja) 2018-11-09 2022-02-22 エル－ニュートラ 断続的断食模倣のための栄養バー
WO2020223522A1 (en) 2019-04-30 2020-11-05 University Of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP7376718B2 (ja) * 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2021247724A1 (en) 2020-06-03 2021-12-09 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
US12109184B2 (en) 2020-06-04 2024-10-08 Faeth Therapeutics, Inc. Personalized methods of treating cancer
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
WO2022130420A1 (en) * 2020-12-17 2022-06-23 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
AU749638B2 (en) * 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
WO2001006983A2 (en) * 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof
CN101868235A (zh) * 2007-11-26 2010-10-20 雀巢产品技术援助有限公司 抑制dsRNA-依赖性蛋白激酶激活和抑制肿瘤生长的组合物和方法

Also Published As

Publication number Publication date
EP2490684A2 (en) 2012-08-29
PT2490684T (pt) 2018-04-02
BR112012009423A2 (pt) 2017-06-13
AU2016201607A1 (en) 2016-03-31
DK2490684T3 (en) 2018-04-09
CA2779282A1 (en) 2011-04-28
EP2490684B1 (en) 2018-01-03
US20210209516A1 (en) 2021-07-08
WO2011050302A2 (en) 2011-04-28
RU2012118588A (ru) 2013-11-27
RU2549954C2 (ru) 2015-05-10
PL2490684T3 (pl) 2018-07-31
ES2659353T3 (es) 2018-03-14
EP2490684A4 (en) 2016-05-04
CN102753162A (zh) 2012-10-24
AU2010310515B2 (en) 2016-01-07
AU2010310515A1 (en) 2012-05-17
WO2011050302A3 (en) 2011-08-25
JP2013508411A (ja) 2013-03-07
AU2016201607B2 (en) 2017-11-30
US20110118528A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
US20210209516A1 (en) Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
Arends et al. ESPEN guidelines on enteral nutrition: non-surgical oncology
AU2020200726B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
RU2734774C2 (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
US10172839B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
US20240358769A1 (en) Compositions and Methods for Treating Inflammation Associated with IL-6
HK1233488B (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
Tan Why Do Cancer Patients Take More Vitamins?

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150902